Researchers are exploring strategies to modulate HLA Class I expression and function as a therapeutic approach in cancer. One potential strategy involves enhancing HLA Class I expression on tumor cells to improve antigen presentation and immune recognition. This can be achieved through genetic engineering or the use of cytokines such as interferons. Another approach is to develop therapies that target specific HLA alleles associated with poor prognosis or immune evasion. Furthermore, understanding the interplay between HLA Class I molecules and immune checkpoint pathways can lead to more effective combination therapies that enhance anti-tumor immunity.
